AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24295013 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 21094025 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive remediation (n=39)
Number of subjects: 77
Study 21094025 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n=38)
Number of subjects: 77
Study 19208714 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses performing endoscopy
Number of subjects: 1888
Study 19208714 — intervention group
Group type: COMPARATOR
Intervention: Doctors performing endoscopy
Number of subjects: 1888
Study 17558641 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 40
Study 17558641 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 40
Study 17558641 — intervention group
Group type: COMPARATOR
Intervention: normal control group
Number of subjects: 40
Study 15190052 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vitamins and minerals (200 mg Mg and 30 mg Zn + 200 mg vitamin C and 150 mg vitamin E)
Number of subjects: 69
Study 15190052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 15190052 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C and E (200 mg vitamin C and 150 mg vitamin E)
Number of subjects: 69
Study 15190052 — intervention group
Group type: COMPARATOR
Intervention: Mg and Zn (200 mg Mg and 30 mg Zn)
Number of subjects: 69
Study 12200215 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex (b.i.d./t.i.d.)
Number of subjects: 43
Study 12200215 — intervention group
Group type: COMPARATOR
Intervention: Extended-release divalproex (qd)
Number of subjects: 43
Study 12200215 — intervention group
Group type: COMPARATOR
Intervention: Both formulations
Number of subjects: 43
Study 9708227 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide for 12 hours, then stopped
Number of subjects: 106
Study 9708227 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide for 36 hours
Number of subjects: 106
Study 9708227 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide for 60 hours
Number of subjects: 106
Study 9708227 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 106
Study 7831492 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of a stroking procedure
Number of subjects: 49
Study 7831492 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement on a multisensory hammock during sleep periods
Number of subjects: 49
Study 7831492 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of stroking procedure and multisensory hammock
Number of subjects: 49
Study 7831492 — intervention group
Group type: COMPARATOR
Intervention: Control group (natural caregiving)
Number of subjects: 49
Study 2477338 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium hydrochloride 1 g twice daily
Number of subjects: 11
Study 2477338 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium hydrochloride 1 g and magnesium hydroxide 500 mg twice daily
Number of subjects: 11
Study 2477338 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 11
Study 334435 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide, 50 mg daily
Number of subjects: 12
Study 334435 — intervention group
Group type: EXPERIMENTAL
Intervention: Metolazone, 5 mg daily
Number of subjects: 12
Study 334435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29366340 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength exercise (squat training, 3 times a week for 8 weeks)
Number of subjects: 40
Study 29366340 — intervention group
Group type: COMPARATOR
Intervention: Control (education programme)
Number of subjects: 40
Study 26848624 — intervention group
Group type: EXPERIMENTAL
Intervention: High hs-CRP levels (≥ 13.1 mg/L)
Number of subjects: 132
Study 26848624 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hs-CRP levels (< 13.1 mg/L)
Number of subjects: 132
Study 25239582 — intervention group
Group type: EXPERIMENTAL
Intervention: Stairclimbing
Number of subjects: 10
Study 25239582 — intervention group
Group type: COMPARATOR
Intervention: Cycle ergometer test
Number of subjects: 10
Study 22925817 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 μg of rectal misoprostol
Number of subjects: 218
Study 22925817 — intervention group
Group type: COMPARATOR
Intervention: 20 intravenous units of oxytocin
Number of subjects: 218
Study 20371660 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/d for 8 weeks)
Number of subjects: 27
Study 20371660 — intervention group
Group type: EXPERIMENTAL
Intervention: Niaspan (2000 mg/d for 16 weeks)
Number of subjects: 27
Study 20371660 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 8 weeks)
Number of subjects: 27
Study 17439513 — intervention group
Group type: EXPERIMENTAL
Intervention: Phloroglucinol/trimethylphloroglucinol (62.2 mg P + 80 mg TMP) two pills three times daily for 7 days
Number of subjects: 307
Study 17439513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 17439513 — intervention group
Group type: EXPERIMENTAL
Intervention: Phloroglucinol/trimethylphloroglucinol
Number of subjects: 307
Study 16270644 — intervention group
Group type: EXPERIMENTAL
Intervention: Certoparin (3000 anti-Xa IU, subcutaneously, once-daily)
Number of subjects: 6124
Study 16270644 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 IU, subcutaneously, three-times daily)
Number of subjects: 6124
Study 16270644 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer patients
Number of subjects: 6124
Study 16270644 — intervention group
Group type: COMPARATOR
Intervention: Non-cancer patients
Number of subjects: 6124
Study 12065973 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental pedicle screw fixation (instrumented)
Number of subjects: 129
Study 12065973 — intervention group
Group type: COMPARATOR
Intervention: No pedicle screw instrumentation (noninstrumented)
Number of subjects: 129
Study 12065973 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (instrumented and noninstrumented)
Number of subjects: 129
Study 12065973 — intervention group
Group type: COMPARATOR
Intervention: Noninstrumented fusion
Number of subjects: 129
Study 12065973 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumented fusion
Number of subjects: 129
Study 10384248 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-management training (education, relaxation, D'Zurilla problem-solving training)
Number of subjects: 21
Study 10384248 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 21
Study 10384248 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-management training
Number of subjects: 21
Study 7610658 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized group A (general population)
Number of subjects: 600
Study 7610658 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (symptom-free 'healthy' subgroup)
Number of subjects: 600
Study 7610658 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (persons with allergic rhinitis)
Number of subjects: 600
Study 7610658 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (asthmatic persons)
Number of subjects: 600
Study 7610658 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sensitization in asthmatic group
Number of subjects: 600
Study 7610658 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sensitization in randomized group
Number of subjects: 600
Study 7610658 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased serum levels of total IgE or specific IgE
Number of subjects: 600
Study 2203273 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50
Study 2203273 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 50
Study 2203273 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 50
Study 215095 — intervention group
Group type: EXPERIMENTAL
Intervention: Procyclidine hydrochloride
Number of subjects: 55
Study 215095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31215727 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide
Number of subjects: 0
Study 31215727 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 1.0 mg
Number of subjects: 0
Study 31215727 — intervention group
Group type: COMPARATOR
Intervention: dulaglutide
Number of subjects: 0
Study 27243916 — intervention group
Group type: EXPERIMENTAL
Intervention: Grouped exercises (GE)
Number of subjects: 20
Study 27243916 — intervention group
Group type: COMPARATOR
Intervention: Separated exercises (SE)
Number of subjects: 20
Study 26214438 — intervention group
Group type: COMPARATOR
Intervention: BIS monitoring group (A)
Number of subjects: 80
Study 26214438 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 23563560 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken collagen hydrolysate (CCH) 2.9 g/d
Number of subjects: 58
Study 23563560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 21147417 — intervention group
Group type: EXPERIMENTAL
Intervention: TrP pressure release
Number of subjects: 20
Study 21147417 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 20
Study 18317438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted Atazanavir (300/100 mg)
Number of subjects: 9
Study 16570047 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg daily)
Number of subjects: 38
Study 12649101 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF mouthwash 150 micro g/day
Number of subjects: 90
Study 12649101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 10874052 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 2 g/kg
Number of subjects: 34
Study 10874052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 10874052 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 34
Study 9288186 — intervention group
Group type: EXPERIMENTAL
Intervention: DC pulsed with PSM-P1 or PSM-P2 (groups 4 and 5)
Number of subjects: 7
Study 9288186 — intervention group
Group type: COMPARATOR
Intervention: PSM-P1 or PSM-P2 alone (groups 1 and 2)
Number of subjects: 7
Study 9288186 — intervention group
Group type: COMPARATOR
Intervention: Autologous DC (group 3)
Number of subjects: 7
Study 7936832 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg birth weight at 12-18 h of age and a second dose 12 h later)
Number of subjects: 40
Study 7936832 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 40
Study 7936832 — intervention group
Group type: COMPARATOR
Intervention: Placebo (i.v. saline)
Number of subjects: 40
Study 3230235 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein meal
Number of subjects: 1
Study 3230235 — intervention group
Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat meal
Number of subjects: 1
Study 3230235 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal containing MCT oil
Number of subjects: 1
Study 3230235 — intervention group
Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 1
Study 29500968 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoenergetic diet high in ALA (3.4 g/d)
Number of subjects: 81
Study 29500968 — intervention group
Group type: COMPARATOR
Intervention: Control diet low in ALA (0.9 g/d)
Number of subjects: 81
Study 29500968 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 81
Study 24190696 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium (150 mg daily recommended dose, administered in three 50 mg doses across the day and evening)
Number of subjects: 24
Study 24190696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24190696 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium
Number of subjects: 24
Study 23038965 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose daunorubicin (60 mg/m2 per administration) and continuous infusion of cytarabine during the second course
Number of subjects: 145
Study 23038965 — intervention group
Group type: COMPARATOR
Intervention: High-dose HAM protocol as a second induction course
Number of subjects: 145
Study 23038965 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose anthracycline antibiotics
Number of subjects: 145
Study 23038965 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol deviations
Number of subjects: 145
Study 21265466 — intervention group
Group type: EXPERIMENTAL
Intervention: Co‐Ir‐vell tablets (test formulation)
Number of subjects: 24
Study 18541232 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogen genistein (54 mg/day)
Number of subjects: 57
Study 18541232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 16420786 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver resection (LR)
Number of subjects: 177
Study 16420786 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion
Number of subjects: 177
Study 16420786 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmentary resections with Pringle maneuver
Number of subjects: 177
Study 16420786 — intervention group
Group type: EXPERIMENTAL
Intervention: Second 100 resections
Number of subjects: 177
Study 12844276 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (n=23)
Number of subjects: 70
Study 12844276 — intervention group
Group type: EXPERIMENTAL
Intervention: tibolone (n=23)
Number of subjects: 70
Study 10846122 — intervention group
Group type: EXPERIMENTAL
Intervention: Wand system
Number of subjects: 40
Study 10846122 — intervention group
Group type: COMPARATOR
Intervention: Traditional syringe
Number of subjects: 40
Study 8619364 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 25 micrograms/kg/day, n = 5
Number of subjects: 16
Study 8619364 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IGF-I 60 micrograms/kg b.i.d., n = 5
Number of subjects: 16
Study 8619364 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IGF-I 15 micrograms/kg b.i.d., n = 6
Number of subjects: 16
Study 8619364 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 16
Study 8619364 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IGF-I
Number of subjects: 16
Study 8619364 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IGF-I
Number of subjects: 16
Study 8619364 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 16
Study 2248030 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid 600 mg daily for 7 days (monotherapy in 53.2% of cases)
Number of subjects: 1186
Study 2248030 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid 600 mg daily for 7 days (in association with antibiotics in 46.8% of cases)
Number of subjects: 1186
Study 7362419 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 0
Study 7362419 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride
Number of subjects: 0
Study 7362419 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose prediction
Number of subjects: 0
Study 31809992 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) enriched with extra-virgin olive oil (EVOO)
Number of subjects: 720
Study 31809992 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (control group)
Number of subjects: 720
Study 30794429 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy snack (Greek yogurt, 198.9 g, 171 kcal, 0 g fat, 17 g protein)
Number of subjects: 18
Study 30794429 — intervention group
Group type: COMPARATOR
Intervention: Nondairy snack (mini sandwich-type cookies, 37.5 g, 175 kcal, 7.5 g fat, 1.3 g protein)
Number of subjects: 18
Study 30794429 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy snack (Greek yogurt)
Number of subjects: 18
Study 27864713 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncovered double bare metal stent (DBS; S&G Biotech Inc.)
Number of subjects: 71
Study 27864713 — intervention group
Group type: COMPARATOR
Intervention: Uncovered single bare metal stent (SBSs; S&G Biotech Inc.)
Number of subjects: 71
Study 27864713 — intervention group
Group type: COMPARATOR
Intervention: Uncovered single bare metal stent (SBSt; Taewoong Medical)
Number of subjects: 71
Study 25156798 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch‐Up (ABC) intervention
Number of subjects: 100
Study 25156798 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 100
Study 22946099 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET) - 40‐60 min cycling at ∼65%, 5 times per week
Number of subjects: 16
Study 22946099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT) - 4‐6 Wingate tests, 3 times per week
Number of subjects: 16
Study 22946099 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ET and SIT
Number of subjects: 16
Study 22005602 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief sleep program (1 session)
Number of subjects: 27
Study 22005602 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended sleep program (2-3 sessions)
Number of subjects: 27
Study 22005602 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 27
Study 19225067 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy or therapy with epidermal growth factor receptor (EGFR) inhibitors
Number of subjects: 8579
Study 19225067 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel therapy every 3 weeks
Number of subjects: 8579
Study 17113676 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine (0-15 min before breakfast and dinner)
Number of subjects: 890
Study 17113676 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (RHI) (30-45 min before breakfast and dinner)
Number of subjects: 890
Study 15161783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragaglitazar 1 mg
Number of subjects: 177
Study 15161783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragaglitazar 4 mg
Number of subjects: 177
Study 15161783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragaglitazar 10 mg
Number of subjects: 177
Study 15161783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg
Number of subjects: 177
Study 15161783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 11309650 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy (LAC, n = 26)
Number of subjects: 50
Study 11309650 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy (OC, n = 24)
Number of subjects: 50
Study 11309650 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy (LAC, n = 20)
Number of subjects: 50
Study 11309650 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy (OC, n = 15)
Number of subjects: 50
Study 11309650 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy (LAC)
Number of subjects: 50
Study 11309650 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy (OC)
Number of subjects: 50
Study 9386068 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Angioplasty
Number of subjects: 125
Study 9386068 — intervention group
Group type: COMPARATOR
Intervention: Coronary Bypass Surgery
Number of subjects: 125
Study 8001939 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples for measurement of plasma zinc levels; Lavage of the vagina and ectocervix with sterile saline solution for measurement of cervicovaginal zinc levels.
Number of subjects: 21
Study 8001939 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 women without anamnesis of vulvovaginal candidiasis).
Number of subjects: 21
Study 3046811 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (5.5 mg/kg administered intravenously)
Number of subjects: 28
Study 3046811 — intervention group
Group type: COMPARATOR
Intervention: Pancreatic enzymes
Number of subjects: 28
Study 3046811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 28300339 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured feedback after the interview
Number of subjects: 38
Study 28300339 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 38
Study 26911396 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/0.05 ml IVI of bevacizumab (IVB group)
Number of subjects: 60
Study 26911396 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/0.05 ml IVI of ranibizumab (IVR group)
Number of subjects: 60
Study 25715386 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 20
Study 25715386 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy
Number of subjects: 20
Study 25715386 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 20
Study 23075915 — intervention group
Group type: COMPARATOR
Intervention: Etravirine alone
Number of subjects: 20
Study 23075915 — intervention group
Group type: COMPARATOR
Intervention: Boceprevir alone
Number of subjects: 20
Study 21393589 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial arterial access
Number of subjects: 51
Study 21393589 — intervention group
Group type: COMPARATOR
Intervention: Femoral arterial access
Number of subjects: 51
Study 18489398 — intervention group
Group type: EXPERIMENTAL
Intervention: DK crush
Number of subjects: 311
Study 18489398 — intervention group
Group type: COMPARATOR
Intervention: Classical crush
Number of subjects: 311
Study 16282244 — intervention group
Group type: EXPERIMENTAL
Intervention: rhAngiostatin at 15 mg or 60 mg twice daily in combination with carboplatin (AUC 5) and paclitaxel (175 mg/m2)
Number of subjects: 24
Study 16282244 — intervention group
Group type: EXPERIMENTAL
Intervention: rhAngiostatin at 15 mg or 60 mg twice daily
Number of subjects: 24
Study 12691140 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 52
Study 12691140 — intervention group
Group type: COMPARATOR
Intervention: Melphalan and prednisone
Number of subjects: 52
Study 10902528 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Learning Environment (VLE)
Number of subjects: 0